{"id":13765,"date":"2009-03-23T00:00:00","date_gmt":"2009-03-23T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/uncategorized\/m004mtg529\/"},"modified":"2019-03-01T15:05:11","modified_gmt":"2019-03-01T15:05:11","slug":"m004mtg529","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m004mtg529\/","title":{"rendered":"CBI’s 2nd Annual Bio\/Pharmaceutical Forum on Effective and Compliant Advisory Boards"},"content":{"rendered":"

Featured Conference<\/b> <\/p>\n

CBI’s 2nd Annual Bio\/Pharmaceutical Forum on Effective and Compliant Advisory Boards<\/b>
Ensure Appropriate Objectives, Structure and Transparency<\/i>
March 23 – 24, 2009 * Vienna, VA<\/b> <\/p>\n

For more information or to register, please visit the conference website<\/a>.<\/b> <\/p>\n

Also see this Forum<\/a> for updates and news from the conference organizers.<\/p>\n

Manufacturers gain an abundance of valuable information from groups of physicians that give their practical, clinical advice on a variety of issues.\u00a0 However, the industry\u2019s relationships with these advisory boards continue to be heavily scrutinized by the public and the government.<\/p>\n

As the industry knows how important these boards are to their medical affairs and marketing teams, it is critical that they demonstrate that interactions with the advisors meet company objectives, while also remaining compliant with regulatory guidelines and are transparent from any potential conflicts or perceived influence by manufacturers.<\/p>\n

In 2008, more than 100 executives benefited from an interactive meeting focused on key strategies to optimize development of advisory boards and ensure objectives are met in a compliant manner.\u00a0 Attend the 2nd Annual Forum to hear updated strategies to ensure effective and compliant advisory board meetings and benchmark again with your peers.<\/p>\n

Key topics being researched for 2009 include:<\/p>\n